Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel dis-eases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′ s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.
CITATION STYLE
Hunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021, April 1). Glp-1 and intestinal diseases. Biomedicines. MDPI AG. https://doi.org/10.3390/biomedicines9040383
Mendeley helps you to discover research relevant for your work.